Protalix BioTherapeutics reported a significant turnaround for the nine months ended September 30, 2026, with net income of $26.1 million compared to a net loss of $1.1 million in the prior year period. This growth was driven by a substantial increase in total revenue to $75.6 million, primarily due to a surge in license and R&D services revenue.
Protalix BioTherapeutics reported Q3 2026 financial results with total year-to-date revenues reaching $75.6 million, a significant increase from $43.6 million in the prior year. The company reported quarterly net income of $4.0 million and reaffirmed its full-year 2026 revenue guidance of $78.0 million to $83.0 million. Management highlighted the ongoing Phase 2 RELEASE study for PRX-115 in uncontrolled gout, with top-line results expected in the second half of 2027.
Term
Q3 2026
“We concluded the first nine months of 2026 with revenues of $75.6 million, reflecting our continued progress and growing financial strength which supports our ability to execute our strategy and advance our key priorities.”
Dror Bashan, President and Chief Executive Officer
“We end the quarter with cash and deposits of $48.5 million, a position of strength that enables us to continue advancing PRX-115 for uncontrolled gout. Uncontrolled gout is a disease with low quality of life and high unmet need and represents a blockbuster uricase market opportunity.”
Dror Bashan, President and Chief Executive Officer